Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Nat Rev Nephrol. 2015 Nov 23;12(2):110–122. doi: 10.1038/nrneph.2015.176

Figure 3. Development of a genetic risk-score associated with treatment-related adverse cardiovascular outcomes on the basis of data from the INVEST and NORDIL trials.

Figure 3

A ‘risk score’ was developed on the basis of the association of nonsynonymous variants (rs16982743, rs893184 and rs4525, in SIGLEC12, A1BG and F5, respectively), with differential outcomes with β-blocker and calcium-channel blocker (CCB) treatment. One point was given for each genotype that conferred higher risk in the CCB group compared to the β-blocker group. Low risk was defined as a risk score of 0 or 1; high risk was defined as a risk score of 2 or 3. #One-sided P value based on a 1-sided hypothesis in the replication cohort. Permission obtained from the American Heart Association © McDonough, C. W. et al. Hypertension 62, 48–54 (2013).